Seer Inc - Class A
Research Seer Inc - Class A (SEER) on Bullrun: market cap USD 112.81M. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerSEER
- ExchangeNASDAQ
- CountryUnited States
- SectorHealthcare
- IndustryBiotechnology
- CurrencyUSD
- Market capUSD 112.81M
- Financial periodQ1 2026
- RevenueUSD 2.71M
- Net income-USD 16.84M
- Free cash flow-USD 15.71M
- Gross margin33.1%
Valuation Snapshot
latest market cap is USD 112.81M.
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | USD 16.58M | -USD 73.60M | -USD 46.25M | 51.1% | -1.28 | USD 47.29M | USD 23.65M | USD 259.31M |
| FY2024 | USD 14.17M | -USD 86.60M | -USD 49.69M | 49.8% | -1.39 | USD 40.75M | USD 25.96M | USD 327.57M |
| FY2023 | USD 16.66M | -USD 86.28M | -USD 66.37M | 51.1% | -1.35 | USD 32.50M | USD 28.26M | USD 396.90M |
| FY2022 | USD 15.49M | -USD 92.97M | -USD 71.05M | 45.8% | -1.49 | USD 53.21M | USD 30.03M | USD 446.99M |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-08-25 | USD 112.81M | n/a | n/a | n/a |
| 2025 | 2025-12-31 | USD 102.88M | n/a | n/a | n/a |
| 2024 | 2024-12-31 | USD 136.59M | n/a | n/a | n/a |
| 2023 | 2023-12-29 | USD 123.82M | n/a | n/a | n/a |
| 2022 | 2022-12-30 | USD 363.32M | n/a | n/a | n/a |
| 2021 | 2021-12-31 | USD 1.41B | n/a | n/a | n/a |
About Seer Inc - Class A
Seer, Inc., a life sciences company, develops and commercializes products to decode the biology of the proteome to improve human health in the United States, China, Australia, Europe, Israel, Japan, and South Africa.
Related stock research
Other Healthcare stocks
Frequently asked questions
What is Seer Inc - Class A's market cap?
Seer Inc - Class A's market capitalization is USD 112.81M.
What does Seer Inc - Class A do?
Seer, Inc., a life sciences company, develops and commercializes products to decode the biology of the proteome to improve human health in the United States, China, Australia, Europe, Israel, Japan, and South Africa. The company offers Proteograph Product Suite, an integrated solution, which includes proprietary engineered nanoparticles, consumables, automation instrumentation, and data analysis software to perform proteomic analysis to provide a solution that can be incorporated by nearly any lab for research use only.